首页> 美国卫生研究院文献>Cancers >Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer
【2h】

Baseline Serum HE4 But Not Tissue HE4 Expression Predicts Response to the Levonorgestrel-Releasing Intrauterine System in Atypical Hyperplasia and Early Stage Endometrial Cancer

机译:基线血清HE4但非组织HE4表达预测非典型增生和早期子宫内膜癌对左炔诺孕酮释放子宫内系统的反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The levonorgestrel-releasing intrauterine system (LNG-IUS) is a conservative management option for atypical hyperplasia (AH) and low grade early stage endometrial cancer (EEC), but around 1 in 3 patients fail to respond to treatment. The aim of this study was to investigate if serum and/or tissue HE4 expression could predict response to LNG-IUS therapy. Patients with AH or presumed Stage I EEC had serum and endometrial samples taken at baseline and at 3-month intervals over 12 months post-insertion of LNG-IUS. 74 patients were recruited and baseline demographics recorded. Of 57 patients for whom response was histologically determinable, 39 (68%) were responders and 18 (32%) non-responders. Mean baseline serum HE4 was significantly lower in responders (62.1 ± 1.1 pM, 95% confidence interval (CI) 52.7–73.2), compared to non-responders (125.6 ± 1.3 pM, 95% CI 74.5–211.7, = 0.014), including when considering age, BMI, menopausal status, smoking status, and histological grade as covariables ( = 0.005). Baseline tissue HE4 expression was not significantly different in responders compared to non-responders ( = 0.999). Responders showed a significant mean reduction (−9.8 ± 3.4%, 95% CI −16.7 to −2.8%, = 0.008) in serum HE4 between baseline and 3 months ( = 0.008), whereas non-responders showed no significant change ( = 0.676). Neither responders nor non-responders showed a significant percentage change in serum HE4 from baseline beyond 3 months ( > 0.05). Change in serum HE4 between baseline and 3 and 6 months and tissue HE4 tissue expression between baseline and 3, 6, and 12 months was not significantly different in responders compared to non-responders ( > 0.05). This study suggests that baseline serum HE4, but not baseline tissue HE4 expression, is independently predictive of response to the LNG-IUS and could be used to guide management decisions.
机译:左炔诺孕酮宫内释放系统(LNG-IUS)是非典型增生(AH)和低度早期子宫内膜癌(EEC)的保守治疗选择,但约有三分之一的患者对治疗无效。这项研究的目的是调查血清和/或组织HE4表达是否可以预测对LNG-IUS治疗的反应。 AH或推测为IEE期的AH患者在插入LNG-IUS后的12个月内,在基线时以及每3个月间隔采集一次血清和子宫内膜样品。招募了74名患者,并记录了基线人口统计数据。在组织学上可确定反应的57例患者中,有39例(68%)有反应,有18例(32%)无反应。与无反应者(125.6±1.3 pM,95%CI 74.5–211.7,= 0.014)相比,有反应者(62.1±1.1 pM,95%置信区间(CI)52.7–73.2)的平均基线血清HE4显着降低。当考虑年龄,BMI,更年期状态,吸烟状态和组织学等级作为协变量时(= 0.005)。与无反应者相比,有反应者的基线组织HE4表达无显着差异(= 0.999)。响应者显示基线至3个月之间血清HE4的平均均值显着降低(-9.8±3.4%,95%CI -16.7至-2.8%,= 0.008),而无响应者无显着变化(= 0.676) )。超过3个月,有反应者和无反应者均未显示血清HE4相对于基线的显着百分比变化(> 0.05)。与无反应者相比,有反应者在基线和3个月与6个月之间血清HE4的变化以及基线与3、6和12个月之间组织HE4组织表达无显着差异(> 0.05)。这项研究表明,基线血清HE4而非基线组织HE4的表达可独立预测对LNG-IUS的反应,并可用于指导管理决策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号